Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema (HAE)

Next Previous
Trial Profile

HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema (HAE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanadelumab (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions
  • Acronyms HELP; HELP Study Extension TM; HELP study OLE
  • Sponsors Dyax; Shire; Takeda

Most Recent Events

  • 05 Apr 2023 Results measuring the impact of long-term lanadelumab treatment on patient-reported outcomes, published in the Annals of Allergy, Asthma and Immunology
  • 13 Feb 2023 According to a Takeda Pharma media release,company announced US FDA's approval of expanded use of TAKHZYRO for prophylaxis to prevent attacks of HAE in pediatric patients 2 to <12 years of age, based on an extrapolation of efficacy data and pharmacokinetics analyses from this study.
  • 14 Nov 2022 Results assessing the comparative effectiveness of lanadelumab and berotralstat for prevention of HAE attacks at 48 weeks using MAIC from HELP OLE and APeX-2 part 2 studies, presented at the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top